On December 30th, at the 2021 Annual Meeting of Sino-Singapore Finance and Economics Online Cloud Summit, Zhang Yuntao, chief scientist and vice president of Sinopharm China Biotechnology, said that the research and development of China's new crown vaccine has always been the world's first phalanx.
Zhang Yuntao introduced that currently 47 varieties of vaccines in China will participate in the batch issuance activities of the State Food and Drug Administration in 2020.
Technically speaking, the level of vaccine research and development at home and abroad is almost synchronized.
Although there is still a gap between my country and the world in the field of biomedicine, the gap between China and foreign countries is the smallest in the field of vaccines.
The research and development of China's new crown vaccine has always been in the first phalanx in the world.
(Chi Hanyu)
Editor in charge: 【Luo Pan】